Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | S100A9 | P06702 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31344514 | 0.80 | HCAR2 (0.45) | HCAR2ACLYS100A9APLNRCHRNB2 | |
| SCHEMBL31097440 | 0.80 | PTGS2 (0.48) | HCAR2ACLYS100A9PTGS2PTGS1 | |
| SCHEMBL1775244 | 0.80 | APLNR (0.59) | HCAR2TDP1S100A9APLNRPTGS2 | |
| SCHEMBL12417957 | 0.80 | PTGS2 (0.48) | HCAR2ACLYS100A9PTGS2PTGS1 | |
| Hydrochloric Acid SCHEMBL28159283 | 0.78 | HCAR2 (0.44) | HCAR2ACLYS100A9APLNRCHRNB2 | |
| SCHEMBL7974914 | 0.77 | HCAR2 (0.38) | HCAR2ACLYS100A9APLNRCHRNB2 | |
| SCHEMBL7968311 | 0.77 | HCAR2 (0.38) | HCAR2ACLYS100A9APLNRCHRNB2 | |
| SCHEMBL7971560 | 0.77 | PSIP1 (0.39) | HCAR2ALDH1A1ACLYS100A9CHRNB2 | |
| SCHEMBL1827300 | 0.76 | HCAR2 (0.41) | HCAR2ALDH1A1HSD17B10TDP1APLNR | |
| SCHEMBL28815836 | 0.76 | ALDH1A1 (0.41) | ALDH1A1HSD17B10TDP1APLNRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118883760-A | Method for detecting related substances in pyridine-3-sulfonyl chloride | 石家庄四药有限公司 | 2024-11-01 | — | — | CN | claimed |
| US-20260034105-A1 | Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors | THE FIRST AFFILIATED HOSPITAL OF XI'AN JIAOTONG UNIVERSITY (CN) | 2026-02-05 | — | — | US | disclosed |
| CN-120142523-A | Method for detecting isomer impurities in vonolamine fumarate starting material and application of method | 北京悦康科创医药科技股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-118883760-A | Method for detecting related substances in pyridine-3-sulfonyl chloride | 石家庄四药有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118883760-A | Method for detecting related substances in pyridine-3-sulfonyl chloride | 石家庄四药有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023159322-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF THE GCN2 KINASE, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2022109001-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-2318390-B1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-05-01 | — | — | EP | disclosed |
| CN-102197033-A | Pyrrole compounds | TAKEDA PHARMACEUTICAL | 2011-09-21 | — | — | CN | disclosed |
| US-20110172275-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172275-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172275-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2318390-A1 | PYRROLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010024451-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056577-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056577-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056577-A1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056577-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | HCAR2 1662/4885ALDH1A1 1448/4885HSD17B10 1434/4885 |
| US-20260034105-A1 | Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors | PIK3R1, PIK3R4, PIK3R2 | HCAR2 379/4885ALDH1A1 1585/4885HSD17B10 946/4885 |
| US-20110172275-A1 | PYRROLE COMPOUNDS | PRLHR, C1R, C1S | HCAR2 1662/4885ALDH1A1 1448/4885HSD17B10 1434/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | HCAR2 2984/4885ALDH1A1 4542/4885HSD17B10 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.